Oversight of DOAC Prescribing Beneficial for A-Fib, VTE Patients
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 5, 2024 -- Direct oral anticoagulant (DOAC) prescribing oversight for off-label prescribing is beneficial while patients are prescribed DOAC, according to a study published online July 30 in Thrombosis and Haemostasis.
Grace C. Herron, from the Frankel Cardiovascular Center at the University of Michigan in Ann Arbor, and colleagues evaluated data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to better characterize when off-label DOAC dosing is occurring and examine the effectiveness of prescribing oversight. The number of alerts generated in response to dosing deviations from the U.S. Food and Drug Administration instructions for atrial fibrillation (AF) and venous thromboembolism (VTE) was examined.
The researchers found that off-label dosing was relatively common among a sample of 789 to 1,022 annual AF patients and 381 to 484 annual VTE patients prescribed a DOAC in the MAQI2 registry. From 2018 to 2022, there were 569 and 162 alerts for AF and VTE patients, respectively. In AF patients, alerts occurred more frequently during follow-up than at initial prescribing (78.2 versus 21.8 percent), while in VTE patients, alerts were more common at initial prescribing (59.9 versus 40.1 percent). Overall, 19.3 and 14.8 percent of AF and VTE alerts, respectively resulted in contact to the prescriber; when the prescriber was contacted, it led to an intervention about 75 percent of the time, with a change in DOAC dosing the most common intervention.
"Oversight of DOAC prescribing using a registry-based approach is effective in identifying errors and initiating the chain of events prompting prescribers to correct errors," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Real-Time AI-Driven Decision Support Aids Catheter Ablation
WEDNESDAY, May 7, 2025 -- An artificial intelligence (AI)-driven model can significantly improve procedural safety in cardiac electrophysiology with real-time decision support...
Faster Walking Pace Cuts Risk for Cardiac Arrhythmias
FRIDAY, April 25, 2025 -- Average and brisk walking pace are associated with a decreased risk for cardiac arrhythmias, according to a study published online April 15 in...
Most Patients Newly Diagnosed With A-Fib Do Not Receive Anticoagulants
WEDNESDAY, April 23, 2025 -- For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed anticoagulants in the year...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.